Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
16.91
-1.43 (-7.80%)
May 18, 2026, 4:00 PM EDT - Market closed
Zenas BioPharma Employees
Zenas BioPharma had 167 employees as of December 31, 2025. The number of employees increased by 37 or 28.46% compared to the previous year.
Employees
167
Change (1Y)
37
Growth (1Y)
28.46%
Revenue / Employee
n/a
Profits / Employee
-$2,545,814
Market Cap
1.07B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 167 | 37 | 28.46% |
| Dec 31, 2024 | 130 | 23 | 21.50% |
| Sep 30, 2024 | 115 | 31 | 36.90% |
| Jun 30, 2024 | 114 | 30 | 35.71% |
| Mar 31, 2024 | 107 | - | - |
| Sep 30, 2023 | 84 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Maravai LifeSciences Holdings | 435 |
| EyePoint | 214 |
| DBV Technologies | 161 |
| Olema Pharmaceuticals | 137 |
| Septerna | 130 |
| MoonLake Immunotherapeutics | 130 |
| Inventiva | 77 |
| Jade Biosciences | 55 |
ZBIO News
- 12 hours ago - Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 days ago - Zenas BioPharma price target raised to $22 from $21 at Morgan Stanley - TheFly
- 4 days ago - Citi opens ‘upside 30-day catalyst watch’ on Zenas BioPharma - TheFly
- 5 days ago - Zenas BioPharma Slides: Corporate presentation - Filings
- 5 days ago - Zenas BioPharma doses first patient in Phase 1 clinical trial of ZB021 - TheFly
- 5 days ago - Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor - GlobeNewsWire
- 5 days ago - Zenas BioPharma reports Q1 EPS ($1.46) vs. (80c) last year - TheFly
- 5 days ago - Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire